<DOC>
	<DOCNO>NCT01371331</DOCNO>
	<brief_summary>The purpose study find much Modigraf absorb use body fast leave body ( Pharmacokinetics ) . The result help decide much Modigraf future give safely child young people follow transplantation .</brief_summary>
	<brief_title>A Study Determine Pharmacokinetics Children Receiving Modigraf ( Tacrolimus Granules ) Following Solid Organ Transplantation</brief_title>
	<detailed_description>The primary objective study determine pharmacokinetics ( PK ) tacrolimus follow oral administration Modigraf , first oral dose steady state paediatric subject undergo de novo allograft transplantation .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>The subject recipient solid organ ( liver , kidney heart ) transplant . Multiorgan transplant acceptable long one organ transplant liver , kidney heart The subject previously receive another organ transplant ( include liver , kidney heart retransplantation ) Subject high immunological risk , define Panel Reactive Antibody ( PRA ) score &gt; 50 % previous 6 month ( applicable renal transplant recipient ) Cold ischemia time donor kidney great 30 hour ( applicable renal transplant recipient ) Subject receive AB0 incompatible donor organ Subject significant renal impairment , define serum creatinine ≥230 μmol/l ( ≥2.6 mg/dl ) pretransplantation ( applicable renal transplant recipient ) Subject significant liver disease , define elevated Alanine Aminotransferase ( ALT ) and/or Asparate Aminotransferase ( AST ) and/or Total Bilirubin level 3 time upper value normal range 28 day prior transplantation ( applicable liver transplant recipient ) Subject pulmonary vascular resistance great 4 Wood unit unresponsive treatment Subjects malignancies history malignancy within last 5 year Subject significant , uncontrolled systemic infection and/or severe diarrhea , vomit , active upper gastrointestinal disorder may affect absorption tacrolimus active peptic ulcer Subject require systemic immunosuppressive medication indication transplantation Recipient donor know HIV , HCV HBV positive Known allergy intolerance steroid , macrolide antibiotic , basiliximab tacrolimus Subject currently participate another clinical trial and/or take investigational drug 3 month prior transplantation Subject unlikely comply visit schedule protocol Subjects take require treat medication substance prohibit protocol</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Heart Transplantation</keyword>
	<keyword>Liver Transplantation</keyword>
</DOC>